市場調査レポート

商品コード

1619138

PD-1およびPD-L1阻害剤の市場規模、シェア、成長分析、製品別、適応症別、流通チャネル別、地域別 - 産業別予測、2024～2031年

PD-1 and PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Product (Nivolumab, Pembrolizumab), By Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC)), By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年12月19日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 810,688円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 948,352円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,086,016円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=152.96円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のPD-1およびPD-L1阻害剤市場規模は、2022年に468億米ドルと評価され、2023年の551億8,000万米ドルから2031年には2,060億米ドルに成長し、予測期間中（2024-2031年）のCAGRは17.9%で成長する見通しです。

PD-1およびPD-L1阻害剤市場は、がん罹患率の上昇と免疫療法に対する意識の高まりに牽引され、変革的な成長を遂げています。これらの革新的な薬剤は免疫回避メカニズムを標的とし、肺がん、黒色腫、膀胱がんなど、さまざまながんにT細胞が対抗できるようにすることに成功しています。2014年にFDAがペムブロリズマブ（キイトルーダ）を承認して以来、ニボルマブやアテゾリズマブなど多数の阻害剤が市場に参入しています。北米はヘルスケアのインフラがしっかりしているため現在市場をリードしているが、免疫療法の認知度が高まるにつれてアジア太平洋地域での成長が見込まれています。メルク社、ロシュ社、ブリストルマイヤーズスクイブ社などの主な企業が積極的に開発を進め、パートナーシップを結んでいます。とはいえ、個別化医療における競合が台頭するなか、高い治療費と副作用が市場拡大を抑制する可能性もあります。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021-2023）

主要企業プロファイル

Akeso Inc.
Alphamab Oncology
Amgen Inc.
AstraZeneca Plc
BeiGene Ltd.
Bristol Myers Squibb Co.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline Plc
Innovent Biologics Inc.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Merck and Co. Inc.

結論と推奨事項

Product Code: SQMIG35I2102

Global PD-1 and PD-L1 Inhibitors Market size was valued at USD 46.8 billion in 2022 and is poised to grow from USD 55.18 billion in 2023 to USD 206.0 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

The PD-1/PD-L1 inhibitor market has experienced transformative growth, driven by rising cancer prevalence and heightened awareness of immunotherapy. These innovative drugs target immune evasion mechanisms, successfully enabling T cells to combat various cancers, including lung, melanoma, and bladder cancers. Since the FDA's approval of pembrolizumab (Keytruda) in 2014, numerous inhibitors have entered the market, including nivolumab and atezolizumab. North America currently leads the market due to its robust healthcare infrastructure, but growth is anticipated in the Asia-Pacific region as awareness of immunotherapy rises. Key players like Merck, Roche, and Bristol-Myers Squibb are actively advancing development and forming partnerships. Nevertheless, high treatment costs and side effects could temper market expansion amidst emerging competition in personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pd-1 and Pd-L1 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pd-1 and Pd-L1 Inhibitors Market Segmental Analysis

Global PD-1 and PD-L1 Inhibitors Market is segmented by product, indication, distribution channel and region. Based on product, the market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. Based on indication, the market is segmented into melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC), bladder cancer, merkel cell carcinoma (MCC) and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market is primarily driven by the escalating prevalence of cancer. With cancer positioned as the second leading cause of death worldwide, the World Health Organization projected approximately 12 million fatalities in 2022 alone. The notable effectiveness of PD-1 and PD-L1 inhibitors in treating diverse cancer types, including lung cancer, melanoma, and bladder cancer, underscores their importance in therapeutic applications. As the incidence of cancer continues to rise and the demand for efficient treatment alternatives grows, the PD-1 and PD-L1 inhibitors market is poised for significant expansion in response to these pressing healthcare needs.

Restraints in the Global Pd-1 and Pd-L1 Inhibitors Market

The global PD-1 and PD-L1 inhibitors market faces significant restraints primarily due to the high costs associated with these therapies. These inhibitors tend to be expensive, thereby restricting access for many patients, especially in developing regions. Moreover, the potential side effects-ranging from fatigue and nausea to diarrhoea-can further deter patients from opting for these advanced treatments. As a result, both healthcare providers and patients might gravitate towards more affordable alternatives like conventional chemotherapy. This situation not only imposes a financial strain on healthcare systems and insurance providers but also affects their willingness to reimburse the costs of these specialized drugs.

Market Trends of the Global Pd-1 and Pd-L1 Inhibitors Market

A significant trend shaping the global PD-1 and PD-L1 inhibitors market is the escalating emphasis on combination therapies. Recent studies indicate that integrating PD-1/PD-L1 inhibitors with other therapeutic modalities, such as chemotherapy or alternative immunotherapies, can markedly enhance treatment efficacy and mitigate the potential for resistance development. Major market players are channeling substantial resources into the formulation and clinical testing of innovative combination regimens, reflecting a collective effort to optimize patient outcomes. This trend is poised to gain momentum in the ensuing years as the medical community endeavors to transcend the constraints associated with PD-1/PD-L1 inhibitors when used as standalone treatments.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global PD-1 and PD-L1 Inhibitors Market Size by Product & CAGR (2024-2031)

Market Overview
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab

Global PD-1 and PD-L1 Inhibitors Market Size by Indication & CAGR (2024-2031)

Market Overview
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma (RCC)
Head and Neck Squamous Cell Cancer (HNSCC)
Bladder Cancer
Merkel Cell Carcinoma (MCC)
Others

Global PD-1 and PD-L1 Inhibitors Market Size by Distribution Channel & CAGR (2024-2031)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global PD-1 and PD-L1 Inhibitors Market Size & CAGR (2024-2031)

North America (Product, Indication, Distribution Channel)
- USA
- Canada
Europe (Product, Indication, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Indication, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, By Indication, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Indication, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Akeso Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alphamab Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Innovent Biologics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck and Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

PD-1およびPD-L1阻害剤の市場規模、シェア、成長分析、製品別、適応症別、流通チャネル別、地域別 - 産業別予測、2024～2031年

PD-1 and PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Product (Nivolumab, Pembrolizumab), By Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC)), By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

PD-1およびPD-L1阻害剤市場規模：製品別

PD-1およびPD-L1阻害剤市場規模：適応症別

PD-1およびPD-L1阻害剤市場規模：流通チャネル別

PD-1およびPD-L1阻害剤市場規模：地域別